Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVB-001 in Platinum-Resistant Ovarian Cancer
NCT05538624Phase 2Terminated
- Sponsor
- Avenge Bio
- Start
- Dec 2022
- Primary completion
- Apr 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of AVB-001 in serous ovarian carcinoma, fallopian tube serous adenocarcinoma (FTC) and primary peritoneal serous carcinoma (PPC) (2 arms), sponsored by Avenge Bio. Primary endpoints: Incidence of Dose Limiting Toxicities at 4 weeks, Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events at 1 year and 1 more. Started Dec 2022; status: terminated.
02
Drugs
AVB-001
03
Conditions
serous ovarian carcinomafallopian tube serous adenocarcinoma (FTC)primary peritoneal serous carcinoma (PPC)
Beyond the preview
Go deeper on NCT05538624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538624.